Continuous treatment with Kesimpta sees RMS patients achievi

Study highlights benefit of initiating high-efficacy therapies early for relapsing multiple sclerosis (RMS) patients, as opposed to changing from lower efficacy therapies later.

Related Keywords

Vienna , Wien , Austria , Ludwig Kappos , European Academy Of Neurology , University Hospital Basel , Novartis , Professor Ludwig Kappos , University Hospital , Cognitive Processing Speed , Relapsing Multiple , European Academy ,